Brain cells affected by HIV infection and Functional consequences

HIV Neuroinvasion and the Consequences of Inadequate CNS Antiretroviral Penetration

Human immunodeficiency virus (HIV) infection presents unique challenges when it comes to central nervous system (CNS) involvement, as the virus establishes early neuroinvasion and creates persistent reservoirs within brain tissue that are particularly difficult to treat. Understanding which specific brain cell populations are targeted by HIV and the long-term consequences of suboptimal CNS drug penetration is crucial for clinicians managing people living with HIV, particularly those experiencing cognitive symptoms despite systemic viral suppression.

HIV Neuroinvasion and Cellular Targets

Early CNS Entry and the Trojan Horse Mechanism

HIV enters the central nervous system remarkably early during the course of infection, with viral presence detectable in cerebrospinal fluid (CSF) within eight days of initial systemic infection12. This rapid neuroinvasion occurs through multiple mechanisms, with the predominant pathway following the "Trojan horse" model, wherein infected CD4+ T lymphocytes and monocytes cross the blood-brain barrier during routine immune surveillance and subsequently infect resident CNS cells23.

The virus can also disrupt blood-brain barrier integrity through effects on tight junction proteins, potentially allowing direct viral entry or facilitating increased immune cell trafficking into the brain3. Studies using natalizumab, which blocks immune cell migration across the blood-brain barrier, have demonstrated profound reductions in CNS HIV DNA levels, confirming that cellular trafficking represents the primary route of neuroinvasion2.

Microglia: The Primary CNS Reservoir

Microglia, the resident macrophages of the central nervous system, serve as the principal target cells for HIV infection within the brain4567. These cells are capable of productive HIV infection and replication, serving as long-lived viral reservoirs that can persist despite antiretroviral therapy68. Microglia possess CD4 receptors and co-receptors (CCR5 and CXCR4) necessary for efficient HIV entry, making them highly susceptible to infection8.

Once infected, microglia undergo several critical changes that contribute to neuropathogenesis. The cells produce and secrete neurotoxic substances including pro-inflammatory cytokines, chemokines, and viral proteins that directly damage neurons and contribute to the development of HIV-associated neurocognitive disorders (HAND)43. Infected microglia also exhibit altered protein expression profiles affecting cell death pathways, DNA replication and repair mechanisms, and redox balance4.

Importantly, microglia can harbor both actively replicating and latent forms of HIV69. In the latent state, integrated proviral DNA remains transcriptionally silent but can be reactivated under appropriate stimuli, contributing to viral persistence even during suppressive antiretroviral therapy610. This latency is maintained through epigenetic mechanisms similar to those observed in peripheral CD4+ T cells, involving histone deacetylases and methyltransferases10.

Astrocytes: Secondary Targets with Amplified Effects

Astrocytes, the most abundant glial cells in the brain, represent a secondary but significant target for HIV infection148. Unlike microglia, astrocytes lack surface CD4 receptors, making them less susceptible to direct HIV infection4. However, they can bind HIV gp120 protein and become infected through CD4-independent mechanisms involving alternative receptors such as CCR5, CXCR4, DC-SIGN, and mannose receptors411.

The frequency of astrocyte infection is typically low, with only 1-3% of astrocytes harboring HIV provirus in infected brains410. However, this low infection rate belies the significant impact these cells can have on CNS pathology. Astrocytes form extensive intercellular networks through their processes, potentially connecting with hundreds of neighboring cells4. Even sparse infection can therefore have far-reaching effects on brain function.

When infected, astrocytes undergo several pathological changes. They exhibit disrupted glutamate transport capacity, which can lead to excitotoxic neuronal damage4. Infected astrocytes also produce inflammatory mediators and can significantly alter the behavior of nearby microglia, enhancing their neurotoxic potential4. Studies have shown that HIV-infected astrocytes dramatically increase the neurotoxicity of HIV-infected microglia through intercellular communication, transforming their normally protective role into a destructive one4.

Functional Consequences of CNS HIV Infection

The infection of microglia and astrocytes leads to a cascade of pathological events that ultimately result in neuronal dysfunction and cognitive impairment. Infected microglia release inflammatory cytokines (IL-1β, IL-6, TNF-α), chemokines, and reactive oxygen species that create a chronic neuroinflammatory environment312. This inflammation can persist even when systemic HIV is well-controlled, suggesting ongoing CNS viral activity or irreversible inflammatory programming12.

HIV proteins, particularly Tat and gp120, have direct neurotoxic effects. Tat protein can cross cell membranes and directly impair synaptic function while promoting neuronal apoptosis3. The protein also interferes with normal neuronal transcriptional pathways and contributes to blood-brain barrier disruption13.

The combined effects of chronic neuroinflammation, direct viral protein toxicity, and disrupted glial cell function manifest clinically as HIV-associated neurocognitive disorders (HAND), which encompass a spectrum from asymptomatic neurocognitive impairment to severe HIV-associated dementia1214.

CNS Penetration Challenges and the CPE Scoring System

Antiretroviral Drug Penetration Barriers

The blood-brain barrier presents a formidable obstacle to antiretroviral drug delivery to the CNS151617. This barrier consists of tightly joined endothelial cells, efficient efflux pumps (particularly P-glycoprotein, MRP, and BCRP), and metabolic enzymes that restrict drug entry17. Many antiretroviral drugs are substrates for these efflux transporters, resulting in subtherapeutic CNS concentrations even when plasma levels are adequate1517.

The challenge is compounded by the fact that different antiretroviral classes have vastly different CNS penetration capabilities. For instance, tenofovir, a commonly used nucleotide reverse transcriptase inhibitor, demonstrates poor CNS penetration and fails to reach effective concentrations in CSF in 77% of patients18. In contrast, drugs like zidovudine and nevirapine achieve better CNS penetration and more effectively suppress viral replication in the brain1920.

The CNS Penetration-Effectiveness (CPE) Scoring System

To address these challenges, researchers developed the CNS Penetration-Effectiveness (CPE) scoring system, which ranks antiretroviral drugs based on their ability to penetrate the CNS and suppress viral replication in this compartment1920. The system has evolved over time, with the current 2010 version using a 4-point scale where higher scores indicate better CNS penetration and effectiveness2122.

The CPE 2010 rankings assign scores as follows:

• Score 4 (Highest penetration): Zidovudine, nevirapine
• Score 3: Abacavir, delavirdine, indinavir/ritonavir, darunavir/ritonavir, fosamprenavir/ritonavir, lopinavir/ritonavir
• Score 2: Emtricitabine, lamivudine, efavirenz, etravirine, indinavir, atazanavir, atazanavir/ritonavir, fosamprenavir, raltegravir, maraviroc
• Score 1 (Lowest penetration): Didanosine, stavudine, tenofovir, nelfinavir, ritonavir, saquinavir, saquinavir/ritonavir, tipranavir/ritonavir, enfuvirtide2122

For combination regimens, individual drug scores are summed to provide an overall CPE score for the treatment regimen1920.

Clinical Validation of CPE Scoring

Multiple studies have validated the clinical relevance of CPE scoring. In the landmark CHARTER study of 467 HIV-positive individuals, lower CPE ranks correlated significantly with higher CSF viral loads1920. Participants with CPE ranks below the median (1.5) had an 88% increased odds of having detectable CSF viral loads compared to those with higher CPE scores19. Importantly, this relationship was independent of plasma viral load, medication adherence, and other clinical factors19.

The association between CPE scores and neurocognitive outcomes has been more complex. While some studies have shown modest improvements in global neurocognitive functioning with higher CPE regimens, the relationship is not as strong or consistent as initially hypothesized23. The effects appear to be most pronounced in patients taking more than three antiretroviral drugs, suggesting that CNS-targeted therapy may require intensified regimens24.

Long-Term Consequences of Inadequate CNS Penetration

CNS Viral Escape and Compartmentalization

One of the most significant consequences of inadequate CNS antiretroviral penetration is the phenomenon of CNS viral escape, defined as the presence of detectable HIV RNA in CSF when plasma viral load is undetectable or significantly higher CSF viral load compared to plasma252627. This condition occurs in approximately 4-21% of antiretroviral-experienced adults and represents independent viral replication within the CNS compartment28.

CNS viral escape often presents with neurological symptoms including cognitive dysfunction, gait abnormalities, tremors, headaches, and behavioral changes2527. The condition can progress to severe encephalitis if left untreated, but typically responds well to optimization of antiretroviral therapy with drugs that have better CNS penetration2526.

The development of viral escape is associated with several risk factors, including poor CNS drug penetration (low CPE scores), history of low CD4 nadir, prolonged HIV infection duration, and specific drug resistance mutations in the CNS2528. Interestingly, many patients with CNS viral escape have unique resistance mutations in CSF that differ from those in plasma, indicating compartmentalized viral evolution28.

Development of CNS-Specific Resistance

Inadequate CNS drug penetration creates a permissive environment for the development of drug resistance mutations specifically within the brain252928. The M184V/I mutation, which confers resistance to emtricitabine and lamivudine, is particularly frequently observed in CSF escape cases28. While this mutation may reduce viral fitness, its presence in combination with thymidine analog mutations (TAMs) can lead to broader nucleoside reverse transcriptase inhibitor cross-resistance28.

The development of CNS-specific resistance is particularly concerning because it can limit future treatment options and may contribute to ongoing neurological complications even after systemic viral suppression is achieved2529.

Persistent CNS Reservoirs and Implications for HIV Cure

The establishment of long-lived HIV reservoirs in microglia and astrocytes represents a major barrier to HIV cure strategies308. These cells can harbor integrated proviral DNA that remains transcriptionally silent but replication-competent, serving as a source of viral rebound if antiretroviral therapy is interrupted306.

CNS reservoirs are particularly challenging because microglia are long-lived cells that do not undergo renewal from peripheral sources during an individual's lifetime30. Additionally, the blood-brain barrier limits the penetration of many potential therapeutic agents designed to target latent reservoirs8.

Evidence for the clinical significance of CNS reservoirs comes from studies demonstrating persistent immune activation in the CNS despite effective systemic viral suppression. In longitudinal studies, only 55-60% of patients achieved normalization of CSF neopterin (a marker of immune activation) after 2-3.5 years of suppressive antiretroviral therapy30, suggesting ongoing low-level viral activity or persistent inflammatory programming.

HIV-Associated Neurocognitive Disorders (HAND)

The long-term consequence of inadequate CNS HIV control is the development of HAND, which affects an estimated 42.6% of people living with HIV in the post-combination antiretroviral therapy era1214. HAND encompasses three categories of increasing severity: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD)1214.

While the introduction of combination antiretroviral therapy has dramatically reduced the incidence of severe HAD from 20% to 3-5%, the prevalence of milder forms remains stubbornly high at 30-50%1214. This persistence suggests that standard antiretroviral regimens may not adequately address CNS HIV replication and inflammation.

The pathophysiology of HAND involves multiple mechanisms, including persistent neuroinflammation, ongoing low-level CNS viral replication, oxidative stress, and the potential neurotoxicity of antiretroviral drugs themselves1312. Recent studies have raised concerns that some newer antiretroviral drugs, particularly integrase inhibitors like dolutegravir, may actually compromise blood-brain barrier integrity, potentially exacerbating HIV-associated CNS pathology13.

Clinical Implications and Management Strategies

The recognition of inadequate CNS penetration as a driver of neurological complications has led to several clinical management strategies. When patients present with neurological symptoms despite systemic viral suppression, clinicians should consider CSF analysis to assess for viral escape3126. If CNS escape is confirmed, optimization of the antiretroviral regimen to include drugs with higher CPE scores is recommended2526.

Several case series have demonstrated significant clinical improvement following regimen optimization in patients with symptomatic CNS viral escape252627. The choice of specific drugs should consider both CNS penetration and the resistance profile of the CNS viral population, which may differ from plasma2528.

For patients with HAND, the evidence for CNS-targeted therapy remains mixed23. While some studies suggest modest benefits from higher CPE regimens, the relationship is not consistently strong enough to recommend routine use of CNS-penetrating drugs in all patients23. Current guidelines emphasize the importance of early treatment initiation and sustained viral suppression, as these factors appear most protective against neurocognitive decline32.

Conclusion

HIV infection of the central nervous system represents a complex interplay between viral neuroinvasion, cellular targeting, and the challenges of achieving adequate drug concentrations across the blood-brain barrier. Microglia serve as the primary CNS reservoir, while astrocytes, though less frequently infected, can significantly amplify neurotoxicity and viral replication. The inadequate penetration of many antiretroviral drugs into the CNS creates a permissive environment for ongoing viral replication, the development of resistance mutations, and the persistence of neuroinflammation.

The long-term consequences of suboptimal CNS treatment include CNS viral escape, the establishment of persistent reservoirs that complicate cure efforts, and the development of HIV-associated neurocognitive disorders that significantly impact quality of life. While the CPE scoring system provides a useful framework for optimizing CNS-targeted therapy, the relationship between drug penetration and clinical outcomes remains complex and requires further investigation.

Future research should focus on developing antiretroviral drugs with improved CNS penetration profiles, identifying biomarkers to predict which patients are at highest risk for CNS complications, and exploring adjunctive therapies to address persistent neuroinflammation. Additionally, CNS reservoirs must be considered in HIV cure strategies, as eradication efforts that fail to address brain-based viral persistence are likely to be unsuccessful.

For clinicians managing people living with HIV, maintaining a high index of suspicion for CNS complications is essential, particularly in patients presenting with cognitive symptoms despite systemic viral suppression. The prompt recognition and treatment of CNS viral escape can lead to significant clinical improvement, while early initiation of antiretroviral therapy remains the most effective strategy for preventing long-term neurological complications.

1. https://www.nih.gov/news-events/news-releases/brain-cells-can-harbor-spread-hiv-virus-body
2. https://www.nature.com/articles/s41598-017-10241-0
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC4741099/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC2579774/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7877929/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC6821723/
7. https://www.umcutrecht.nl/en/over-ons/nieuws/details/feb-16-the-central-nervous-system-a-reservoir-for-hiv
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC8402376/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC6953890/
10. https://journals.asm.org/doi/10.1128/jvi.03333-13
11. https://www.sciencedirect.com/science/article/pii/S1286457915001069
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5382956/
13. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1118580/full
14. https://hiv.guidelines.org.au/management/neurological-disease/hiv-associated-central-nervous-system-diseases/
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7483662/
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3227164/
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2678986/
18. https://academic.oup.com/jac/article/73/2/484/4604697
19. https://jamanetwork.com/journals/jamaneurology/fullarticle/795059
20. https://natap.org/2009/HIV/082709_01.htm
21. https://www.natap.org/2019/HIV/134.full.pdf
22. https://www.natap.org/2010/HIV/Effectsnervous.pdf
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC9227894/
24. https://www.iasusa.org/wp-content/uploads/2011/11/19-4-137.pdf
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4753349/
26. https://pmc.ncbi.nlm.nih.gov/articles/PMC11402493/
27. https://pubmed.ncbi.nlm.nih.gov/38578230/
28. https://journals.lww.com/jaids/fulltext/2017/06010/temporal_patterns_and_drug_resistance_in_csf_viral.15.aspx
29. https://www.medrxiv.org/content/10.1101/2023.03.03.23286708v2.full.pdf
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4586130/
31. https://memory.ucsf.edu/sites/memory.ucsf.edu/files/wysiwyg/UCSF_HIV%20Dementia_Providers_11-6-17.pdf
32. https://www.infectiousdiseaseadvisor.com/features/assessing-the-risk-factors-of-neurocognitive-decline-in-hiv-individuals/
33. https://www.neurology.org/doi/10.1212/WNL.0000000000001016
34. https://www.ninds.nih.gov/health-information/disorders/neurological-complications-hiv
35. https://pubmed.ncbi.nlm.nih.gov/38588024/
36. https://www.nature.com/articles/s41598-017-12758-w
37. https://www.encephalitis.info/types-of-encephalitis/other/human-immunodeficiency-virus-hiv-and-the-brain/
38. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.843801/full
39. https://www.sciencedirect.com/science/article/abs/pii/S0165572815001587
40. https://www.aidsmap.com/news/oct-2023/hiv-brain-does-it-correlate-neurocognitive-symptoms
41. https://www.mdpi.com/1999-4915/16/7/1082
42. https://www.hopkinsmedicine.org/health/conditions-and-diseases/hiv-and-aids/neurological-complications-of-hiv
43. https://www.sciencedirect.com/science/article/abs/pii/S1879625719300471
44. https://www.imrpress.com/journal/JIN/23/9/10.31083/j.jin2309172/htm
45. https://www.thewellproject.org/hiv-information/hiv-and-brain
46. https://academic.oup.com/jid/article/206/2/275/2192379
47. https://onlinelibrary.wiley.com/doi/10.1155/2016/2587094
48. https://pubmed.ncbi.nlm.nih.gov/18195140/
49. https://academic.oup.com/ofid/article/6/7/ofz277/5529443
50. https://pmc.ncbi.nlm.nih.gov/articles/PMC7770011/
51. https://www.sciencedirect.com/science/article/pii/S2589004224004577
52. https://hnrp.hivresearch.ucsd.edu/index.php/research/investigator-resources/resources-offered/laboratory-pharmacology-a-biomarkers-resources-242/cns-penetration-effectiveness-ranks-2010
53. https://www.sciencedirect.com/science/article/pii/S0166223620301491
54. https://www.mdpi.com/1999-4915/17/4/572
55. https://www.natap.org/2011/CROI/croi_139.htm
56. https://www.nature.com/articles/s41598-020-60684-1
57. https://www.medicalalgorithms.com/cns-penetration-effectiveness
58. https://jnnp.bmj.com/content/83/Suppl_2/A8.4
59. https://www.sciencedirect.com/science/article/pii/S0022356524176264
60. https://www.sciencedirect.com/science/article/abs/pii/S0006295223002708
61. https://emedicine.medscape.com/article/1166894-overview
62. https://www.sciencedirect.com/science/article/pii/S0959438822001313
63. https://www.mdpi.com/2218-273X/12/7/894
64. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2019.00362/full
65. https://www.sciencedirect.com/science/article/abs/pii/S1471489220300837
66. https://www.jci.org/articles/view/167417
67. https://www.sciencedirect.com/science/article/pii/S2666379124004907
68. https://pubmed.ncbi.nlm.nih.gov/38366730/
69. https://bhiva.org/wp-content/uploads/2024/10/P050.pdf
70. https://www.nature.com/articles/s41582-023-00813-2
71. https://www.sciencedirect.com/science/article/abs/pii/S2352301819301432
72. https://academic.oup.com/cid/article/76/3/e629/6671582
73. https://www.sciencedirect.com/science/article/pii/S1201971219301626
74. https://onlinelibrary.wiley.com/doi/full/10.1002/rmv.2536
75. https://pmc.ncbi.nlm.nih.gov/articles/PMC9172586/
76. https://www.jci.org/articles/view/176358
77. https://academic.oup.com/jid/article/231/2/e429/7896343
78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10615506/
79. https://academic.oup.com/cid/article/67/8/1182/4959767
80. https://onlinelibrary.wiley.com/doi/10.1111/hiv.13142
81. https://pmc.ncbi.nlm.nih.gov/articles/PMC2763187/
82. https://pmc.ncbi.nlm.nih.gov/articles/PMC3022370/
83. https://escholarship.org/content/qt0sm692bk/qt0sm692bk_noSplash_07b4401bfff3c91ee3941c2e6cc5d9fa.pdf
84. https://www.jwatch.org/ac201301280000004/2013/01/28/central-nervous-system-penetration-effectiveness
85. https://www.neurology.org/doi/10.1212/WNL.0b013e31821670fb
86. https://www.askgileadmedical.com/docs/biktarvy/biktarvy-central-nervous-system-penetration
87. https://www.aidsmap.com/news/feb-2010/studies-confirm-drugs-penetrate-brain-control-hiv-better-and-improve-symptoms-brain
88. https://www.jwatch.org/na34952/2014/06/17/antiretroviral-therapy-regimens-with-superior-cns
89. https://pmc.ncbi.nlm.nih.gov/articles/PMC10081682/